MedTrace Logo

A Study of Armored CAR T Cells in People With Cancer

NCT07783477 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-08-28

No results posted yet for this study

Summary

The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

Conditions

Interventions

DRUG

DLL3-SAVVYZ-IL18 CAR T cell

DLL3-SAVVYZ-IL18 CAR T cell

Sponsors & Collaborators

Principal Investigators

  • Adam Schoenfeld, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07783477 on ClinicalTrials.gov